Thursday, July 9, 2026

Drug profile · INN

tividenofusp alfa-eknm

tividenofusp alfa-eknm (AVLAYAH) is an FDA-listed pharmaceutical active ingredient. Associated with Denali Therapeutics. Route of administration: powder,for solution. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 1
News articles 1
Drug details — tividenofusp alfa-eknm

Quick answer

tividenofusp alfa-eknm (AVLAYAH) is an FDA-listed pharmaceutical active ingredient. Associated with Denali Therapeutics. Route of administration: powder,for solution. Current US regulatory status: approved.

Key facts

INN tividenofusp alfa-eknm
Brand AVLAYAH
Route POWDER,FOR SOLUTION
Formulation INJECTION

Approval history

Authority Status Date
FDA approved

Recent coverage

Pipeline programs

  1. tividenofusp alfa Phase 3 · Denali Therapeutics · Mucopolysaccharidosis II
  1. US 12378540

    Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12358928

    Compounds, compositions and methods

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12180211

    Compounds, compositions and methods

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11958840

    Compounds, compositions and methods

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11884944

    Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11851440

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11851433

    Compounds, compositions and methods

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11834439

    Compounds, compositions, and methods

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11643446

    Progranulin variants

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11591316

    Compounds, compositions, and methods

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11427571

    Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 11306077

    Compounds, compositions and methods

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 11236100

    Modulators of eukaryotic initiation factor 2B, compositions and methods

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 11214565

    Compound, compositions, and methods

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 11174262

    Compounds, compositions and methods

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 11111235

    Compounds, compositions, and methods

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 11072618

    Compounds, compositions and methods

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 10851088

    Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10604535

    Compounds, compositions and methods

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 10590114

    Compounds, compositions, and methods

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is tividenofusp alfa-eknm?

tividenofusp alfa-eknm (AVLAYAH) is an FDA-listed pharmaceutical active ingredient. Associated with Denali Therapeutics. Route of administration: powder,for solution. Current US regulatory status: approved.

What is the brand name for tividenofusp alfa-eknm?

AVLAYAH is a marketed brand name for tividenofusp alfa-eknm. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tividenofusp alfa-eknm?

tividenofusp alfa-eknm has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.